FDA Staff Travels on Drug Industry Dollars
The Center for Public Integrity reports that FDA officials circumvent the prohibition on accepting trips from drug and medical device manufacturers.
The Center for Public Integrity reports that FDA officials circumvent the prohibition on accepting trips from drug and medical device manufacturers.
“Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?” An article in the Schizophrenia Bulletin, by Dr. John Bola that dares to question the validity of the unexamined treatment paradigm in schizophrenia:
A series of news reports may be a rude awakening to the fact that there are hidden, potentially lethal hazards of participating in clinical trials—and those hazards are concealed from the human guinea pigs who are enticed with promise of easy money.
On Wednesday, the FDA Pediatric Advisory Committee handed the agency a mixed message regarding warnings about selective list of
psychotropic drugs prescribed for treating ADHD symptoms.
AHRP Urges Actions to Minimize Risks for Children prescribed psychotropic drugs: Action is needed to protect children from widespread prescribing of psychoactive drugs for ill-defined behavioral symptoms.
Mental Screening ties to drug companies exposed. Screening for Mental Health (Harvard affiliated) received $500K from Eli Lillly. See: https://ahrp.org/children/mentalscreen/LillyCheck.jpg
TeenScreen hired high powered PR firms whose business is to create promotional campaigns to increase drug sales for its clients.
"More than 7 million americans are estimated to have misused stimulant drugs."
"This is out-of-control use of drugs that have profound cardiovascular consequences. We have got a potential public health crisis. I think patients and families need to be made aware of these concerns."
"During a hastily called press conference yesterday,” the FDA announced that it is considering ADDITIONAL warnings on the labels of SSRI drugs—Prozac, Paxil, Zoloft, et al.
"After another four months or so on antidepressants, bringing me to a total of 10 months between the steroids and antidepressants, I was suddenly flipped into this hypomania."
Authors of the American College of Neuropsychopharmacology Task Force on SSRIs and Suicidal Behavior in Youth: their known ties to the pharmaceutical industry
Even Dr. Robet Temple, FDA Medical Policy Director of the Center for Drug Evaluation & Research dismisses the claimed finidings of a flawed, but highly trumpeted recent SSRI study published in the American Journal of Psychiatry. The study was sponsored by the National Institute of Mental Health.